Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alice Di Rocco

Showing results (41-50 of 106) with videos related to

Pageof 11
Sort By:
Leukemia & Lymphoma|December 4, 2020
Relapsed/refractory diffuse large B-cell lymphoma patients. A multicenter retrospective analysis of eligibility criteria for car-T cell therapyAlice Di Rocco, Antonio Cuneo, Arianna Di Rocco, et al.
Hematological Oncology|January 13, 2017
Second cancer incidence in primary mediastinal B-cell lymphoma treated with methotrexate with leucovorin rescue, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin regimen with or without rituximab and mediastinal radiotherapy: Results from a monoinstitutional cohort analysis of long-term survivorsVitaliana De Sanctis, Marco Alfò, Alice Di Rocco, et al.
Haematologica|December 20, 2024
Molecular measurable residual disease by immunoglobulin gene rearrangements on circulating tumor DNA predicts outcome in diffuse large B-cell lymphomaRoberta Soscia, Giovanni Manfredi Assanto, Irene Della Starza, et al.
Cancers|May 13, 2023
Long-Term Host Immune Modulation Following Tisagenlecleucel Administration in Patients with Diffuse Large B-Cell Lymphoma and B-Lineage Acute Lymphoblastic LeukemiaAnna Guarini, Giulia Radice, Nadia Peragine, et al.
Haematologica|October 15, 2020
Prognostic impact of somatic mutations in diffuse large B-cell lymphoma and relationship to cell-of-origin: data from the phase III GOYA studyChristopher R Bolen, Magdalena Klanova, Marek Trneny, et al.
Leukemia Research|July 4, 2012
Atypical presentation of anaplastic large T-cell lymphoma mimicking an articular relapse of rheumatoid arthritis in a patient treated with etanercept. A case report and literature reviewFederico De Angelis, Alice Di Rocco, Clara Minotti, et al.
Leukemia & Lymphoma|December 3, 2013
Identification of pharmacogenomic markers of clinical efficacy in a dose-dense therapy regimen (R-CHOP14) in diffuse large B-cell lymphomaStefania Nobili, Cristina Napoli, Benedetta Puccini, et al.
Blood Advances|August 8, 2025
Routine Prophylaxis with Levetiracetam offers no benefit in CD19 CAR-T for LBCL: a Multicenter Propensity-matched StudyEugenio Galli, Roberta Di Blasi, Alice Di Rocco, et al.
Bone Marrow Transplantation|September 4, 2023
Impact of SARS-CoV-2 vaccination and passive prophylaxis with tixagevimab/cilgavimab on CAR-T patients: a three-year regional experience from the Italian covid pandemicEugenio Galli, Alice Di Rocco, Ilaria Pansini, et al.
Leukemia & Lymphoma|April 29, 2020
Direct-acting antivirals in relapsed or refractory hepatitis C virus-associated diffuse large B-cell lymphomaMichele Merli, Irene Defrancesco, Carlo Visco, et al.
Pageof 11

Showing results (41-50 of 106) with videos related to

Sort By:
Pageof 11
Leukemia & Lymphoma|December 4, 2020
Relapsed/refractory diffuse large B-cell lymphoma patients. A multicenter retrospective analysis of eligibility criteria for car-T cell therapyAlice Di Rocco, Antonio Cuneo, Arianna Di Rocco, et al.
Hematological Oncology|January 13, 2017
Second cancer incidence in primary mediastinal B-cell lymphoma treated with methotrexate with leucovorin rescue, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin regimen with or without rituximab and mediastinal radiotherapy: Results from a monoinstitutional cohort analysis of long-term survivorsVitaliana De Sanctis, Marco Alfò, Alice Di Rocco, et al.
Haematologica|December 20, 2024
Molecular measurable residual disease by immunoglobulin gene rearrangements on circulating tumor DNA predicts outcome in diffuse large B-cell lymphomaRoberta Soscia, Giovanni Manfredi Assanto, Irene Della Starza, et al.
Cancers|May 13, 2023
Long-Term Host Immune Modulation Following Tisagenlecleucel Administration in Patients with Diffuse Large B-Cell Lymphoma and B-Lineage Acute Lymphoblastic LeukemiaAnna Guarini, Giulia Radice, Nadia Peragine, et al.
Haematologica|October 15, 2020
Prognostic impact of somatic mutations in diffuse large B-cell lymphoma and relationship to cell-of-origin: data from the phase III GOYA studyChristopher R Bolen, Magdalena Klanova, Marek Trneny, et al.
Leukemia Research|July 4, 2012
Atypical presentation of anaplastic large T-cell lymphoma mimicking an articular relapse of rheumatoid arthritis in a patient treated with etanercept. A case report and literature reviewFederico De Angelis, Alice Di Rocco, Clara Minotti, et al.
Leukemia & Lymphoma|December 3, 2013
Identification of pharmacogenomic markers of clinical efficacy in a dose-dense therapy regimen (R-CHOP14) in diffuse large B-cell lymphomaStefania Nobili, Cristina Napoli, Benedetta Puccini, et al.
Blood Advances|August 8, 2025
Routine Prophylaxis with Levetiracetam offers no benefit in CD19 CAR-T for LBCL: a Multicenter Propensity-matched StudyEugenio Galli, Roberta Di Blasi, Alice Di Rocco, et al.
Bone Marrow Transplantation|September 4, 2023
Impact of SARS-CoV-2 vaccination and passive prophylaxis with tixagevimab/cilgavimab on CAR-T patients: a three-year regional experience from the Italian covid pandemicEugenio Galli, Alice Di Rocco, Ilaria Pansini, et al.
Leukemia & Lymphoma|April 29, 2020
Direct-acting antivirals in relapsed or refractory hepatitis C virus-associated diffuse large B-cell lymphomaMichele Merli, Irene Defrancesco, Carlo Visco, et al.
Pageof 11